Transcode Therapeutics, Inc. Logo

Transcode Therapeutics, Inc.

Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.

RNAZ | US

Overview

Corporate Details

ISIN(s):
US89357L1052
LEI:
Country:
United States of America
Address:
6 LIBERTY SQUARE, 2109 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Transcode Therapeutics, Inc. is a clinical-stage oncology company focused on developing targeted therapies for metastatic disease. The company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, a key regulator of metastasis. Transcode utilizes its proprietary TTX drug delivery platform, which employs tunable iron oxide nanoparticles to deliver RNA-based therapeutics specifically to cancer cells, addressing a significant challenge in the field. This platform technology has demonstrated broad potential in pre-clinical models across numerous cancer types, including breast, pancreatic, and ovarian cancer. The company aims to eradicate metastatic tumor cells that have spread from the primary tumor. Transcode recently acquired Polynoma LLC to enhance its immuno-oncology and metastatic prevention capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Transcode Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Transcode Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Transcode Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.